AmerisourceBergen Gains Ability To Track Oncology Drug Use Through Acquisition
This article was originally published in The Pink Sheet Daily
ABC will fold medical education and analytical research firm Network for Medical Communications & Research into its manufacturing services business.
You may also be interested in...
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.